ERBB2 and breast carcinoma: In this study, we propose to develop a therapy for trastuzumab-resistant HER2+ breast cancer with the combined use of a small molecular inhibitor against WIP1 (GSK2830371), anti-miR-21 oligonucleotides (antagomiR21), and trastuzumab.